• New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

• Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

• Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and manage ordering support through a single conversational interface.

“Researchers today are navigating growing scientific complexity, increasing volumes of data and expanding workflow choices,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “QIA Agent is designed to simplify how researchers interact with scientific information, workflow guidance and operational support through a single AI-powered experience. By embedding conversational AI into our digital ecosystem, we aim to help customers move faster from questions to decisions across Sample to Insight workflows.”

As laboratories generate increasing amounts of data and workflows become more complex, researchers are seeking more intuitive ways to access scientific expertise, technical guidance and operational support. Conversational AI is emerging as a new interface layer for scientific workflows, helping reduce friction across research, purchasing and laboratory operations.

QIA Agent addresses these challenges by connecting QIAGEN’s product information, protocols, technical documentation, ordering tools and support resources through a natural-language interface.

It is accessible with or without login, allowing users to engage immediately while offering a more personalized experience when signed in. Logged-in users can access individual pricing, order history and account-specific information, making interactions more relevant and efficient. With more than 260,000 users already registered on “My QIAGEN” at www.qiagen.com, the platform builds on an established digital customer base.

Key features and benefits include:

• Natural-language scientific guidance: Researchers can interact with QIA Agent through a conversational interface and receive guidance linked to relevant QIAGEN products, protocols, technical information and recommended next steps.

• Connected product and workflow intelligence: QIA Agent combines product information, protocols, technical documentation and support resources to support decision-making for experiment planning and product selection.

• Integration with QIAGEN digital services: The platform connects researchers with existing QIAGEN tools, including the Experiment Configurator, Order Status Checker, Product Availability Checker and Help Center to create a seamless interface from experiment planning through post-purchase support.

• Ordering and support access in one place: Researchers can check product availability, track orders and access relevant support information without moving across multiple systems.

• Improved laboratory efficiency: By simplifying access to scientific information, digital tools and operational support, QIA Agent is designed to help laboratories save time, improve productivity through faster and more informed decisions.

QIA Agent is now publicly accessible via www.qiagen.com to all QIAGEN customers worldwide. It is currently intended for research use and is not designed for diagnostic applications.

The launch of QIA Agent forms part of QIAGEN’s broader efforts to apply AI and digital technologies across its customer-facing ecosystem. By embedding AI-enabled assistance into laboratory workflows, QIAGEN aims to make scientific information, product selection and operational support easier to access for researchers worldwide.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.

Category: Corporate

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520732949/en/